



Novel Therapies Committee - Terms of Reference

Mandate

The mandate of the Novel Therapies Committee is to advance research, education, and advocacy initiatives around non-factor replacement therapies in hemophilia (including bispecific antibodies, hemostatic rebalancing agents, and gene therapy). We will serve as a resource for collaborative research and educational projects initiated by AHCDC members and develop Canadian practice documents and guidelines.

Membership

Chair – The Chair can be self-nominated from one of the existing Novel Therapies Committee member, and selected by consensus recommendation of the members; if no existing member is interested in serving as the chair, we will seek out candidates from the AHCDC membership community.

Members – Members should have substantial clinical or research experience with non-factor replacement therapies, as evidenced by involvement in clinical trials, registry studies, and/or educational and advocacy work in this area.

The committee is made up of approximately 6-8 members, balanced between adult and pediatric treaters.

Meetings/ Communication

The members will generally meet by teleconference at the call of the Chair approximately twice a year, or more frequent if needed. The Committee will report to the membership through the Executive Committee.

The Committee will also maintain liaison with the Research Committee when undertaking research projects.

Costs

Sufficient to hold 2 to 3 teleconferences per year.

Current membership

Chair	Dr. Linda Sun
Members	Dr. M. Belletrutti Dr. R. Khalife Dr. A. Lee Dr. D. Matino Dr. J. Stoffman

Dr. J. Teitel
Dr. M. Warner